Elmind Capital LP Buys Shares of 984,931 Viridian Therapeutics, Inc. $VRDN

Posted by George Bondi on Aug 26th, 2026

Elmind Capital LP bought a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 984,931 shares of the company’s stock, valued at approximately $18,093,182,000. Viridian Therapeutics comprises 4.5% of Elmind Capital LP’s investment portfolio, making the stock its 8th largest position.

A number of other hedge funds have also recently made changes to their positions in VRDN. Perceptive Advisors LLC grew its stake in shares of Viridian Therapeutics by 108.1% in the fourth quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock worth $94,689,000 after acquiring an additional 1,580,303 shares during the last quarter. Morgan Stanley raised its position in shares of Viridian Therapeutics by 805.6% in the 4th quarter. Morgan Stanley now owns 1,738,225 shares of the company’s stock worth $54,094,000 after purchasing an additional 1,546,284 shares during the last quarter. Avoro Capital Advisors LLC bought a new position in Viridian Therapeutics in the 4th quarter worth about $46,680,000. Parkman Healthcare Partners LLC bought a new position in Viridian Therapeutics in the 2nd quarter worth about $25,306,000. Finally, Vanguard Group Inc. grew its position in Viridian Therapeutics by 29.6% during the 4th quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock valued at $174,650,000 after purchasing an additional 1,280,161 shares during the last quarter.

Viridian Therapeutics Price Performance

NASDAQ VRDN opened at $24.18 on Wednesday. Viridian Therapeutics, Inc. has a one year low of $13.18 and a one year high of $34.29. The stock has a 50-day moving average of $20.14 and a 200 day moving average of $20.81. The company has a debt-to-equity ratio of 0.43, a quick ratio of 16.95 and a current ratio of 16.95. The company has a market capitalization of $2.74 billion, a price-to-earnings ratio of -7.18 and a beta of 0.91.

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.02). The company had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.06 million. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. On average, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.07 EPS for the current year.

Insider Activity at Viridian Therapeutics

In other news, insider Jennifer Tousignant sold 14,212 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on VRDN shares. Weiss Ratings lowered shares of Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Wells Fargo & Company upgraded shares of Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $20.00 to $31.00 in a research note on Monday, June 29th. Stifel Nicolaus set a $39.00 price target on shares of Viridian Therapeutics in a report on Wednesday, May 13th. Evercore set a $26.00 price target on shares of Viridian Therapeutics in a research report on Friday, May 15th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $39.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, June 30th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $38.54.

View Our Latest Analysis on Viridian Therapeutics

About Viridian Therapeutics

(Free Report)

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.